CABINET presents cabozantinib as a new treatment option for NETs
- PMID: 39317817
- DOI: 10.1038/s41571-024-00949-0
CABINET presents cabozantinib as a new treatment option for NETs
References
Original article
-
- Chan, J. A. et al. Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2403991 (2024) - DOI - PubMed - PMC
LinkOut - more resources
Full Text Sources
